- * Male or female
- * Aged ≥ 18 to ≤ 65 years
- * A diagnosis of C1-INH HAE or FXII/PLG HAE;
- * For subjects with C1-INH HAE: ≥ 4 HAE attacks over a consecutive 2-month period during the 3 months before Screening, as documented in the subject's medical record.
Hereditary Angioedema
A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)
NCT03712228 | PHASE 2 | INTERVENTIONAL
This is a multicenter, randomized, placebo-controlled, parallel-arm, phase 2 study to investigate the clinical efficacy, pharmacokinetics, and safety of CSL312 as prophylaxis to prevent attacks in subjects with HAE.
Trial Information
If interested, contact clinicaltrials@cslbehring.com for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
Donald S. Levy
Orange,California,United States,92868
Allergy & Asthma Clinical Research
Walnut Creek,California,United States,94598
Immunoe Health Centers
Centennial,Colorado,United States,80112
Institute for Asthma and Allergy
Chevy Chase,Maryland,United States,20815
The Mount Sinai Hospital
New York,New York,United States,10029
Pennsylvania State University
Hershey,Pennsylvania,United States,17033
AARA Research Center
Dallas,Texas,United States,75231
Campbelltown Hospital
Campbelltown,New South Wales,Australia,2560
University of Alberta
Edmonton,Alberta,Canada,T6G2B7
Allergy and Clinical Immunology McMaster University
Hamilton,Ontario,Canada,L8S4K1
Ottawa Allergy Research Corp
Ottawa,Ontario,Canada,K1G6C6
Charit Universittsmedizin Berlin
Berlin,Germany,10117
Universittsklinikum Frankfurt GoetheUniversitt
Frankfurt,Germany,60590
Hautklinik und Poliklinik der Universittsklinik Mainz
Mainz,Germany,55131
HZRM Hmophilie Zentrum Rhein Main GmbH
Mörfelden-Walldorf,Germany,64546
Barzilai University Medical Center
Ashkelon,Israel,7830604
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov